Vanda Pharmaceuticals Stock
Price
Target price
€3.68
€3.68
2.220%
0.08
2.220%
€5.00
12:36 / Tradegate
WKN: A0JJT3 / Symbol: VNDA / Name: Vanda Pharma / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Vanda Pharmaceuticals Stock
Vanda Pharmaceuticals gained 2.220% today.
The community is currently still undecided about Vanda Pharmaceuticals with 2 Buy predictions and 0 Sell predictions.
As a result the target price of 5 € shows a positive potential of 35.87% compared to the current price of 3.68 € for Vanda Pharmaceuticals.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Vanda Pharmaceuticals stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Vanda Pharmaceuticals in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Vanda Pharmaceuticals vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Vanda Pharmaceuticals | 2.220% | 3.468% | -15.166% | -43.622% | -7.732% | -72.672% | - |
Salarius Pharmaceuticals Inc. | 1.470% | -21.538% | -20.000% | -76.920% | -26.486% | -98.684% | -99.992% |
Ardelyx Inc. | -0.870% | -3.641% | -22.870% | 71.742% | 19.031% | 28.024% | - |
Evolus Inc | 1.560% | 1.563% | -2.985% | 66.667% | 39.037% | 31.287% | - |
Comments
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Show more
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for VNDA provided by MarketBeat